Memorial Sloan Kettering Cancer Center
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Inclusion Criteria: * Be willing and able to provide written informed consent for the trial. * Be ≥ 15 years of age on day of signing informed consent. * Have histologically- or cytologically- confirmed metastatic ACC with symptomatic liver metastases. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or * Adequate performance status: 1. Patients \< 16 years of age: Lansky ≥ 50% 2. Patients ≥ 16 years of age: Karnofsky ≥ 50% * Have measurable disease based on RECIST v1.1. * Have radiologic documentation of extrahepatic tumor, defined as extrahepatic metastases.…
All participants will first undergo ablative RT
After completion of ablative RT, all subjects may begin pembrolizumab treatment